Loading organizations...
§ Private Profile · Nijmegen, Gelderland, The Netherlands
Diagnostic technology developer offering point-of-care blood coagulation analysis, focused on personalized medicine for bleeding disorders.
Based in Nijmegen, Netherlands, Enzyre develops point-of-care diagnostic technology for blood coagulation analysis to facilitate personalized medicine for patients with bleeding disorders. The company's proprietary platform utilizes chemiluminescent enzyme substrates and single-use microfluidic cartridges to measure enzymatic activity from small blood samples. This hardware system enables near-patient testing and real-time data sharing with physicians through a connected mobile application, streamlining clinical workflows. To scale its operations, Enzyre has raised €12 million in Series A financing from a syndicate of institutional investors that includes Takeda Ventures, Oost NL, i&i Biotech Fund, and Novalis Biotech. The enterprise also maintains a strategic development partnership with Takeda to advance its diagnostic devices for home-based hemophilia management. The company was founded in 2016 as a spin-off from Radboud University Medical Center by co-founders Guido Maertens and Waander van Heerde.
Enzyre has raised $13.5M across 2 funding rounds.
Enzyre has raised $13.5M in total across 2 funding rounds.
Enzyre has raised $13.5M in total across 2 funding rounds.
Enzyre's investors include Pieter Rhemrev, Demcon Investment, Karel Kubias, Novalis Biotech, Takeda Ventures, Wim van Criekinge.
Enzyre has raised $13.5M across 2 funding rounds. Most recently, it raised $11.9M Series A in November 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 2, 2022 | $11.9M Series A | Pieter Rhemrev | Demcon Investment, Karel Kubias, Novalis Biotech, Takeda Ventures | Announced |
| Jul 27, 2020 | $1.6M Venture Round | WIM VAN Criekinge | — | Announced |